Market Overview

Benzinga's Top Upgrades

Share:
Benzinga's Top Upgrades
Related THOR
Thoratec Receives Approval From FDA For Full Expansion Of HeartMate III™ U.S. IDE Clinical Trial
Credit Suisse Reiterates Outperform, Raises Price Target On Thoratec On Updated LVAD Estimates
Thoratec Hits 52-Week High on Strong Q1, Pipeline Progress - Analyst Blog (Zacks)
Related AMD
Jefferies Says Now Is A Great Time To Buy Semiconductors
Morgan Stanley Digs Into AMD's New Product Roadmap
Semiconductor Stock Outlook - May 2015 - Zacks Analyst Interviews (Zacks)

Analysts at Goldman Sachs upgraded Thoratec (NASDAQ: THOR) from “neutral” to “buy.” The target price for Thoratec is set to $46. Thoratec's shares closed at $38.31 on Friday.

Wedbush upgraded Advanced Micro Devices (NYSE: AMD) from “neutral” to “outperform.” The target price for Advanced Micro Devices has been raised from $4.50 to $5. AMD's shares closed at $3.83 on Friday.

Analysts at Cowen & Company upgraded St. Jude Medical (NYSE: STJ) from “underperform” to “market perform.” The target price for St. Jude Medical has been raised from $38 to $53. St. Jude Medical's shares closed at $55.16 on Friday.

Analysts at Miller Tabak upgraded Dunkin' Brands Group (NASDAQ: DNKN) from “hold” to “buy.” The target price for Dunkin' Brands Group has been raised from $46 to $53. Dunkin' Brands Group's shares closed at $45.68 on Friday.

Latest Ratings for THOR

DateFirmActionFromTo
May 2015BarclaysMaintainsEqual-weight
May 2015JP MorganMaintains
Apr 2015OppenheimerMaintainsOutperform

View More Analyst Ratings for THOR
View the Latest Analyst Ratings

Posted-In: top upgradesUpgrades Analyst Ratings

 

Related Articles (AMD + DNKN)

Around the Web, We're Loving...